Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Mishima E, Conrad M
Additional Safety Information: Not recommended for individuals who are pregnant, breastfeeding, or planning to become pregnant or breastfeed
The SURPASS-3 study was started to study the efficacy and safety of TZP versus basal insulin degludec in diabetic patients inadequately controlled by metformin with or without an SGLT2-i for 52 weeks (7274)
It was developed at Novo Nordisk and introduced to the literature by Raun and colleagues in 1998 under a title that has defined it ever since: the first selective growth hormone secretagogue
Aouina H, Bamri A, Vesin A, Danno K, Aubry E, Faure C, Boujedaini N
US$ 20.65
US$ 29.56
US$ 22.55
US$ 29.62
US$ 23.19
US$ 23.51
US$ 27.36
US$ 22.39
US$ 24.40
